NCT00640328View on ClinicalTrials.gov

Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

May 31, 2010

Study Completion Date

October 31, 2011

Conditions
Multiple Sclerosis
Interventions
DRUG

Ofatumumab 100

100mg

DRUG

Ofatumumab 300

300mg

DRUG

Ofatumumab 700

700mg

DRUG

Placebo

matching placebo

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00640328 - Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients | Biotech Hunter | Biotech Hunter